{
  "success": true,
  "pagesUsed": [
    2,
    3,
    4,
    12,
    13,
    14,
    15
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To detect a RRR of in the incidence of severe COVID-19/death in the AZD7442 group compared to the placebo group",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective",
        "text": "To evaluate the efficacy of AZD7442 compared to placebo in the primary analysis population",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Safety Objective",
        "text": "To evaluate the safety and tolerability of a single IM dose of AZD7442",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "A composite of either severe COVID-19 or death from any cause through Day 29. Severe COVID-19 is characterized by a minimum of either pneumonia (fever, cough, tachypnea, or dyspnea, AND lung infiltrates) or hypoxemia (SpO2 < 90% in room air and/or severe respiratory distress) and a WHO Clinical Progression Scale score of 5 or higher",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint",
        "text": "Incidence of severe COVID-19/death in the primary analysis population",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Safety Endpoint",
        "text": "Safety data through Day 8 from the participants in the sentinel group and monitoring for hypersensitivity reactions",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adult patients with COVID-19 at high-risk of progression (modified full analysis set) Summary measure: Relative Risk Reduction (RRR) using CMH method.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Death from any cause",
            "text": "Death occurring through Day 29",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Treatment discontinuation",
            "text": "Participant discontinues study or intervention prior to Day 29",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "AZD7442 600 mg IM single dose vs Placebo",
        "analysisPopulation": "Adult patients with COVID-19 at high-risk of progression (modified full analysis set)",
        "variableOfInterest": "A composite of either severe COVID-19 or death from any cause through Day 29",
        "summaryMeasure": "Relative Risk Reduction (RRR) using CMH method"
      },
      {
        "id": "est_2",
        "name": "Secondary Efficacy Estimand",
        "populationSummary": "Adult patients with COVID-19 (primary analysis population) Summary measure: Relative Risk Reduction (RRR).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Death from any cause",
            "text": "Death occurring during the analysis period",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "AZD7442 600 mg IM single dose vs Placebo",
        "analysisPopulation": "Adult patients with COVID-19 (primary analysis population)",
        "variableOfInterest": "Incidence of severe COVID-19 or death",
        "summaryMeasure": "Relative Risk Reduction (RRR)"
      },
      {
        "id": "est_3",
        "name": "Safety Estimand - Sentinel Group",
        "populationSummary": "First 20 participants dosed (Sentinel Group) Summary measure: Incidence and frequency of adverse events.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of monitoring before Day 8",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "AZD7442 600 mg IM single dose vs Placebo",
        "analysisPopulation": "First 20 participants dosed (Sentinel Group)",
        "variableOfInterest": "Safety data and hypersensitivity monitoring through Day 8",
        "summaryMeasure": "Incidence and frequency of adverse events"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 2,
      "exploratoryObjectives": 0,
      "totalEndpoints": 3,
      "totalEstimands": 3
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To detect a RRR of in the incidence of severe COVID-19/death in the AZD7442 group compared to the placebo group",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective",
        "text": "To evaluate the efficacy of AZD7442 compared to placebo in the primary analysis population",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Safety Objective",
        "text": "To evaluate the safety and tolerability of a single IM dose of AZD7442",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "A composite of either severe COVID-19 or death from any cause through Day 29. Severe COVID-19 is characterized by a minimum of either pneumonia (fever, cough, tachypnea, or dyspnea, AND lung infiltrates) or hypoxemia (SpO2 < 90% in room air and/or severe respiratory distress) and a WHO Clinical Progression Scale score of 5 or higher",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint",
        "text": "Incidence of severe COVID-19/death in the primary analysis population",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Safety Endpoint",
        "text": "Safety data through Day 8 from the participants in the sentinel group and monitoring for hypersensitivity reactions",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adult patients with COVID-19 at high-risk of progression (modified full analysis set) Summary measure: Relative Risk Reduction (RRR) using CMH method.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Death from any cause",
            "text": "Death occurring through Day 29",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Treatment discontinuation",
            "text": "Participant discontinues study or intervention prior to Day 29",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "AZD7442 600 mg IM single dose vs Placebo",
        "analysisPopulation": "Adult patients with COVID-19 at high-risk of progression (modified full analysis set)",
        "variableOfInterest": "A composite of either severe COVID-19 or death from any cause through Day 29",
        "summaryMeasure": "Relative Risk Reduction (RRR) using CMH method"
      },
      {
        "id": "est_2",
        "name": "Secondary Efficacy Estimand",
        "populationSummary": "Adult patients with COVID-19 (primary analysis population) Summary measure: Relative Risk Reduction (RRR).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Death from any cause",
            "text": "Death occurring during the analysis period",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "AZD7442 600 mg IM single dose vs Placebo",
        "analysisPopulation": "Adult patients with COVID-19 (primary analysis population)",
        "variableOfInterest": "Incidence of severe COVID-19 or death",
        "summaryMeasure": "Relative Risk Reduction (RRR)"
      },
      {
        "id": "est_3",
        "name": "Safety Estimand - Sentinel Group",
        "populationSummary": "First 20 participants dosed (Sentinel Group) Summary measure: Incidence and frequency of adverse events.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of monitoring before Day 8",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "AZD7442 600 mg IM single dose vs Placebo",
        "analysisPopulation": "First 20 participants dosed (Sentinel Group)",
        "variableOfInterest": "Safety data and hypersensitivity monitoring through Day 8",
        "summaryMeasure": "Incidence and frequency of adverse events"
      }
    ]
  }
}